Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review

Apixaban is a potent, direct, oral, reversible, and highly selective inhibitor of FXa (inhibitory constant = 0.08 nM [0.037 ng/mL] at 25 °C) [12, 13] that does not require antithrombin III for antithrombotic activity [14]. Apixaban inhibits free and clot-bound FXa, as well as prothrombinase activity, which inhibits clot growth [15]. By inhibiting FXa, apixaban decreases thrombin generation and thrombus development. It has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin [16]. In a rabbit arteriovenous shunt thrombosis model, apixaban inhibited thrombus formation in a dose-dependent manner (half maximal inhibitory concentration = 329 nM) [12].

The maximum plasma concentration (C_max) of apixaban occurs 3–4 h after oral administration [17, 21]. The absorption of apixaban appears to occur primarily in the small intestine and decreases progressively throughout the gastrointestinal tract [22]. Compared with oral administration, the bioavailability of 2.5 mg of apixaban solution was approximately 60% and 84% lower when released in the distal small bowel and ascending colon, respectively [22]. For oral doses up to 10 mg, the absolute bioavailability of apixaban is ~ 50% [23, 24], resulting from the incomplete absorption [18] and first-pass metabolism in the gut and liver [25, 26].

Food does not have a clinically significant effect on the bioavailability of apixaban. Apixaban exposure following administration of 10 mg of apixaban with food (high-fat, high-calorie meal) was similar to apixaban exposure when administered in the fasting state, with geometric mean ratios (fed/fasted) for C_max and area under the concentration–time curve from time zero to infinity (AUC_0–∞) [90% confidence interval (CI)] of 1.10 (1.004, 1.197) and 1.04 (1.004, 1.086) [17]. In another study using the apixaban commercial 5-mg tablet, administration with a high-fat, high-calorie meal reduced apixaban C_max and AUC_0–∞ by 14.9% and 20.1%, respectively [27]. The exposure reduction was considered not clinically significant.

Several alternatives for administering apixaban were also studied. When 10 mg of apixaban (2 × 5-mg tablets) was crushed and suspended in 30 mL of water, C_max and AUC_0–∞ met bioequivalence criteria compared with administration of whole tablets [27]. When apixaban was crushed and mixed with 30 g of applesauce, C_max and AUC_0–∞ decreased by 21.1% and 16.4%, respectively. Administration of an apixaban 5-mg crushed tablet via nasogastric tube (NGT) resulted in exposure (C_max and AUC_0–∞) equivalent to that obtained after administration of 5 mg of apixaban as a solution (12.5 mL × 0.4 mg/mL) via an oral syringe [28]. An apixaban solution formulation is being investigated for use in patients unable to swallow oral dosage forms [28, 29], such as certain hospitalized patients and children in ongoing pediatric studies. Oral administration of apixaban solution resulted in exposure (AUC_0–∞) equivalent to that obtained following administration of apixaban tablets [28]. The bioavailability of apixaban solution administered via NGT and flushed with 5% dextrose in water or infant formula (Similac^®; Abbott Laboratories, Abbott Park, IL, USA) was found to be generally comparable: bioequivalent with 5% dextrose in water and 19% lower C_max and 8% lower AUC_0–∞ with infant formula to that of apixaban solution administered orally. These results suggest both 5% dextrose in water and infant formula could be used to flush apixaban solution through an NGT [28]. In addition, administration of apixaban solution via NGT in the presence of a liquid meal challenge with BoostPlus^® (Nestlé HealthCare Nutrition, Fremont, MI, USA) resulted in a modest reduction in apixaban exposure (C_max and AUC_0–∞ values 32% and 19% lower, respectively), compared with the corresponding values observed after administration of apixaban solution via an oral syringe [28]. These results support several alternatives for administering apixaban that maintain exposure similar to that of intact oral tablets [28].

The in vitro plasma protein binding of apixaban in humans is approximately 87% and it is predominantly bound to albumin [30]. When studied in subjects administered apixaban, protein binding was ~ 93% in healthy subjects and comparable in subjects with end-stage renal disease (ESRD; creatinine clearance [CrCl] < 15 mL/min) and in subjects with mild-to-moderate hepatic impairment, suggesting that protein binding was not altered by ESRD or mild-to-moderate hepatic impairment [31, 32].

The volume of distribution is approximately 21 L, suggesting distribution mainly into extracellular fluid, which comprises vascular and interstitial fluid [3, 4, 23, 24]. The blood to plasma ratio of apixaban is 0.9:1 in humans, suggesting that apixaban is uniformly distributed between plasma and red blood cells [16]. It is unknown whether apixaban or its metabolites are excreted in human breast milk. A tissue distribution study in rats showed that apixaban was excreted in milk (~ 10% of the maternal dose) [33]. The milk to plasma AUC_0–∞ ratio in rats was 30:1, indicating that apixaban can accumulate in milk.

Total plasma clearance of apixaban is ~ 3.3 L/h and renal clearance is ~ 0.9 L/h (~ 27% of total clearance), as determined by two intravenous (IV) studies [3, 4, 23, 24]. The apparent elimination half-life (t_1/2) is ~ 12 h [17, 21, 34‐36]. Elimination involves multiple pathways, including metabolism as well as biliary and renal elimination of the unchanged parent compound and direct intestinal excretion [18, 37]. Apixaban is not a high-extraction-ratio drug.

The metabolic pathways for apixaban include O-demethylation, hydroxylation, and sulfation of hydroxylated O-demethyl apixaban [18], with metabolism primarily occurring via cytochrome P450 (CYP) 3A4/5, with minor contributions from CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2J2 [25]. After an oral dose of apixaban, unchanged apixaban is the major drug-related component in human plasma with no active circulating metabolites present [18]. When a 20-mg radiolabeled dose was administered orally, 56.0% of the dose was recovered in feces and 24.5% was eliminated in urine and unchanged apixaban was the major component in both feces (60.7%) and urine (87.7%). When bile was collected following administration of the 20-mg dose, the recovery was 46.7% in feces and 28.8% in urine. The radioactivity identified in biliary excreta during a 5-h collection window was approximately 5% of total radioactivity recovery, suggesting that biliary excretion is a minor pathway of elimination and that fecal recovery consisted of both absorbed and unabsorbed drug because the fecal recovery of total radioactivity was larger than that seen in bile.

In experiments conducted in bile duct cannulated rats and dogs, 20–50% of an IV dose of apixaban was excreted fecally, which identified direct intestinal excretion as a contributor to apixaban elimination [26]. The direct intestinal excretion appears to play a role in humans as well. In an open-label, randomized, crossover study in which subjects were administered activated charcoal either 2 or 6 h after a single oral dose of apixaban 20 mg, the results showed that apixaban terminal t_1/2 was reduced from 13.4 h to approximately 5 h while there was little effect on peak apixaban plasma concentrations [37]. This increased elimination of apixaban by activated charcoal may be due to adsorption of unabsorbed apixaban and interruption of apixaban reabsorption after biliary and/or direct intestinal excretion.

The total and renal elimination of apixaban were characterized in two IV studies including 50 healthy subjects administered a single IV dose of apixaban (0.5–5 mg) [23, 24]. In these studies, apixaban renal clearance was 27% of total clearance on average.

Apixaban exposure increases proportionally with doses up to 10 mg, but at doses ≥ 25 mg, less-than-proportional increases are observed, likely due to dissolution-limited bioavailability [17, 34, 38]. The dose-proportionality analysis showed that apixaban exposure increased proportionally to dose across the approved dose range (2.5–10 mg) [34]. Exposure was less than proportional for doses greater than 10 mg; this appeared to be driven by the less-than-proportional increases in exposure following administration of the 25- and 50-mg doses. Dose proportionality was further assessed across 2.5–10 mg using single-dose PK data from 17 phase I studies (data on file). This analysis showed that both C_max and AUC_0–∞ showed a dose-proportional increase across the 2.5- to 10-mg dose range.

There is no time dependency in apixaban pharmacokinetics and single-dose data predict multiple-dose pharmacokinetics. Following BID doses of apixaban, steady-state concentrations were reached by day 3, consistent with the apparent elimination t_1/2 of 12 h, as illustrated in Fig. 3 [21]. Apixaban showed a modest accumulation (less than two fold) with BID dosing consistent with the apparent elimination t_1/2.

A study in healthy male and female subjects, aged either 18–40 years (young) or 65–79 years (elderly), found that the C_max of apixaban was similar in both age groups but the AUC_0–∞ was 32% higher in the elderly subjects [39]. The study showed a direct relationship between apixaban clearance and creatinine clearance, suggesting that renal function may have contributed to the differences in apixaban exposures between groups. Population-PK analyses using intensive PK data collected in phase I studies and sparse PK data from phase II and III studies for each approved indication showed that age alone had a small impact on apixaban exposure [40‐42]. In NVAF, for example, 80- and 40-year-old subjects are predicted to have 5% higher and 11.5% lower daily AUC values at steady state, respectively, compared with a reference 65-year-old subject. In addition, results from sub-analyses of phase III trials with apixaban found that age did not affect the benefit–risk profile of apixaban [10, 11, 43‐45], and therefore no dose adjustment of apixaban is required based on age alone [3, 4].

In the study of healthy subjects that evaluated age, C_max and AUC_0–∞ of apixaban were approximately 18% and 15% higher in female than in male subjects. This difference in exposure is considered modest and unlikely to be clinically significant [39]. Population-PK analyses also showed a < 20% increase in apixaban daily exposure in female versus male subjects for approved indications [40‐42]. Further, no meaningful differences were seen between male and female subjects in the primary efficacy or safety outcomes in the key phase III trials for apixaban [5, 6, 10, 11, 44]. No dose adjustment of apixaban is required based on sex [3, 4].

In healthy subjects, those with low body weight (≤ 50 kg) had approximately 27% and 20% higher apixaban C_max and AUC_0–∞, respectively, compared with the reference body weight group (65–85 kg) [46]. Conversely, those with a high body weight (≥ 120 kg) had approximately 31% and 23% lower apixaban C_max and AUC_0–∞, respectively, compared with the reference group [46]. Apixaban renal clearance was similar across weight groups [46]. In addition, population-PK analyses showed that body weight explained the between-subject variability for apparent volume of distribution and the effect was less than proportional [40‐42]. Results from subanalyses of phase III trials with apixaban found that body weight did not affect the benefit–risk profile of apixaban [10, 11, 47] and no dose adjustment is required based on body weight alone [3, 4].

In healthy subjects, pharmacokinetics in Asian (Japanese and Chinese) subjects were similar to pharmacokinetics in non-Asian subjects [34‐36]. Population-PK analyses showed that Asian subjects with NVAF or VTE had a 13.5% and 20.2% increase in apixaban AUC, respectively; however, this difference was not considered clinically meaningful [41, 42]. Polymorphisms of CYP3A5 and P-glycoprotein (P-gp) have been suggested as contributing factors to ethnic differences in apixaban pharmacokinetics [48, 49]. Results from subanalyses of phase III trials with apixaban found that race did not affect the benefit–risk profile of apixaban [50]. No dose adjustment is required based on race or ethnicity [3, 4].

Consistent with the limited contribution of renal clearance to the overall clearance of apixaban (~ 27%), the impact of renal impairment on apixaban exposure was modest. Renal impairment showed no effect on apixaban C_max. The regression analysis of AUC_0–∞ vs. CrCl showed that in subjects with mild (CrCl of 65 mL/min), moderate (40 mL/min), and severe (15 mL/min) renal impairment, apixaban AUC_0–∞ increased by 16%, 29%, and 44%, respectively, compared with healthy subjects with normal renal function (CrCl of 100 mL/min) [51]. Population-PK analyses showed consistent results [40‐42]. For example, NVAF subjects with mild, moderate, and severe renal impairment are estimated to have approximately 9%, 28%, and 55% higher daily AUC values at steady state, respectively, compared with subjects with normal renal function. In subjects with ESRD maintained on dialysis, apixaban AUC_0–∞ following administration after completion of a dialysis session was 36% higher than that in healthy subjects with normal renal function. Hemodialysis was associated with a reduction in apixaban exposure of approximately 14% [31].

The limited renal contribution to apixaban elimination and the modest increase in apixaban exposure in subjects with ESRD undergoing hemodialysis suggest that, from a PK perspective, apixaban could be used without dose modification in these patients. However, it is important to note that subjects with severe renal impairment (CrCl < 30 mL/min in VTE prevention orthopedic studies or CrCl < 25 mL/min in NVAF and VTE treatment studies) or ESRD maintained on hemodialysis were excluded in clinical efficacy and safety studies of apixaban. Limited clinical outcomes data indicate that the benefit–risk profile of apixaban appears to be maintained in the presence of severe renal impairment: those randomized to apixaban experienced lower bleeding rates compared with warfarin among 269 subjects with NVAF who had CrCl 25 to < 30 mL/min in the phase III ARISTOTLE study, consistent with the results in the overall population [52]. Further evaluation of the benefit–risk profile of apixaban in patients with NVAF and ESRD is ongoing (NCT02942407, NCT02933697). The prescribing guidance depends on the approved indication and the region. For example in the USA, no dose adjustment is recommended for apixaban due to renal function alone based on the phase I results in subjects undergoing hemodialysis [4, 31]. In patients with NVAF, a reduced dose of apixaban (2.5 mg BID) should be administered if patients have at least two of the following characteristics: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL, consistent with the apixaban dose-reduction criteria used in NVAF phase III clinical trials [5, 6], as these are considered inherent risk factors for bleeding in the NVAF population [53]. In Europe, a lower dose of apixaban (2.5 mg BID) should be taken by patients with NVAF with severe renal impairment (CrCl 15–29 mL/min) and apixaban is not recommended in patients with CrCl < 15 mL/min, or in patients undergoing dialysis [3].

Mild (Child–Pugh Class A) and moderate (Child–Pugh Class B) hepatic impairment had no appreciable effect on the pharmacokinetics of apixaban. Point estimates (90% CI) vs. healthy subjects for AUC_0–∞ were 1.03 (0.798, 1.32) and 1.09 (0.849, 1.41), respectively, for subjects with mild or moderate hepatic impairment [32]. Protein binding in subjects with mild or moderate hepatic impairment (data on file: unbound fraction of 7.1% and 6.8%, respectively) was comparable to that in healthy subjects (data on file: 7.9%). No dose adjustment is required in patients with mild or moderate hepatic impairment [4]. Tirona et al. evaluated the impact of nonalcoholic fatty liver disease on apixaban pharmacokinetics and reported no difference between healthy subjects and subjects with nonalcoholic fatty liver disease [54]. The pharmacokinetics of apixaban in subjects with severe (Child–Pugh Class C) hepatic impairment was not evaluated. As patients with severe hepatic impairment may have intrinsic coagulation abnormalities and there is little clinical experience with apixaban in these patients, use of apixaban is not recommended in patients with severe hepatic impairment [3, 4].

Limited PK data are available from a multiple-dose PK study of apixaban using an oral solution (0.4 mg/mL) in pediatric patients at risk of VTE and who had an indwelling central venous catheter [55]. Of the eight patients enrolled, six patients aged 12 to < 18 years received apixaban 0.66 mg/m² BID for 10 days, and two patients aged 6–11 years received apixaban 0.60 mg/m² BID for 10 days. Apixaban pharmacokinetics was characterized by a two-compartment population-PK model, with first-order absorption and elimination. Allometric scaling of body weight was used to adjust for differences in oral clearance and volume of distribution. The oral clearance of apixaban was 4.86 L/h in the adolescent subjects, consistent with that in adults (data on file, [40‐42]). A single-dose apixaban PK/PD study and multiple efficacy and safety studies in pediatric patients are ongoing (NCT01707394, NCT02464969, NCT02981472, NCT02369653).

In vitro assessment showed that apixaban did not induce or inhibit major CYP enzymes or interfere with transport of P-gp substrates [25]. When apixaban was evaluated for the potential to inhibit CYP3A4, CYP2C9, CYP2C19, and CYP2D6 in human liver microsomes, half-maximal inhibitory concentration values were > 45 μM [25]. For induction effects of apixaban, there was little or no effect on the activities of CYP1A2, CYP2B6, and CYP3A4/5 in the primary cultures of human hepatocytes, nor any significant increase in messenger RNA levels. Therefore, drug–drug interactions in which apixaban alters the pharmacokinetics of other drugs are not expected. Apixaban did not inhibit digoxin transport in Caco-2 cells [26]. The lack of effect on P-gp was confirmed by a phase I study of co-administration of apixaban (20 mg QD) with digoxin (0.25 mg QD), a P-gp substrate, which showed no impact on digoxin C_max or AUC [56].

Apixaban is a substrate for CYP enzymes, primarily CYP3A4/5, and for efflux transporters P-gp and breast cancer resistance protein (BCRP) [25, 26]. Both P-gp and BCRP are human ATP-binding cassette transporters with a significant overlap in substrate specificity and BCRP-specific inhibitors are limited [57]. Modulation of CYP3A4 and P-gp by other agents is the most likely mechanism for PK interactions involving apixaban, and therefore this was the focus of phase I drug–drug interaction studies as summarized in Fig. 5.

The largest effect on apixaban exposure was observed in the presence of ketoconazole, a representative strong inhibitor of CYP3A4 and P-gp, and rifampin, a representative strong inducer of both CYP3A4 and P-gp [23, 58]. Following co-administration with ketoconazole, apixaban C_max and AUC_0–∞ were approximately 1.6- and two-fold higher, respectively, than values observed following administration of apixaban alone [58]. Following co-administration with rifampin, apixaban C_max and AUC_0–∞ were 42% and 54% lower, respectively, than values following administration of apixaban alone [23]. Other strong inhibitors of CYP3A4 and P-gp (e.g., itraconazole, ritonavir) would be expected to increase blood apixaban concentrations, and simultaneous use with other strong inducers of CYP3A4 and P-gp (e.g., carbamazepine, phenytoin, St. John’s wort) would be expected to reduce blood apixaban concentrations [23, 58]. The use of strong CYP3A4 inhibitors and inducers was prohibited in apixaban phase III clinical trials. Given the limited clinical experience, the prescribing guidance for strong inhibitors or inducers of CYP3A4 and P-gp depends on the approved indication and the region. Concomitant administration of apixaban with strong inhibitors of both CYP3A4 and P-gp is generally not recommended, with some regions, including the USA, recommending to reduce the apixaban dose by 50% for patients who would otherwise be receiving apixaban doses of 5 mg or 10 mg BID [4]. Co-administration of apixaban with strong inducers of both CYP3A4 and P-gp is generally not recommended, especially for patients receiving treatment for VTE owing to the potential decrease in efficacy associated with decreased apixaban exposure. Some geographic regions, including Europe, recommend that co-administration with such strong inducers should be used with caution for VTE prevention in orthopedic patients and in patients with NVAF [3].

Co-administration with less potent CYP3A4 or P-gp inhibitors resulted in a more modest effect on apixaban exposure. Following administration with naproxen, a P-gp inhibitor with no activity toward CYP3A4 or BCRP, at an intestinal concentration of 6–10 mM [26], apixaban C_max and AUC_0–∞ were 61% and 54% higher, respectively, than values following administration of apixaban alone [59]. Similarly, following co-administration with diltiazem, a moderate inhibitor of CYP3A4 and a weak inhibitor of P-gp, apixaban C_max and AUC_0–∞ were 31% and 40% higher, respectively, than values observed following administration of apixaban alone [58]. Clarithromycin, an inhibitor of P-gp and a strong inhibitor of CYP3A4, led to a 1.3- and 1.6-fold increase in mean apixaban C_max and AUC_0–∞, respectively [3]. No dose adjustment of apixaban is required when administered with agents that are not considered strong inhibitors of both CYP3A4 and P-gp, such as naproxen, diltiazem, and clarithromycin [3, 4].

Agents with no known effect on either CYP3A4 or P-gp (e.g., atenolol or famotidine) had little (< 20%) or no effect on apixaban exposure [4, 56, 60]. Following co-administration of atenolol and apixaban, mean apixaban C_max and AUC_0–∞were 18% and 15% lower, respectively, than when apixaban was administered alone [56]. The administration of apixaban with famotidine, a commonly prescribed histamine H₂-receptor antagonist, had no effect on apixaban C_max or AUC_0–∞. These results demonstrate that elevated gastric pH is unlikely to affect the pharmacokinetics of apixaban [60]. In addition, as famotidine is a potent inhibitor of the uptake transporter protein human organic cation transporter-3, and a moderate inhibitor of human organic cation transporter-1 and human organic cation transporter-2, the results indicate that apixaban is not a substrate for these transporters [60].

After combined administration of LMWH, enoxaparin (40-mg single dose), with apixaban (5-mg single dose), an additive effect on anti-FXa activity was observed [64]. Agents associated with serious bleeding that are not recommended for concomitant use with apixaban include unfractionated heparins and heparin derivatives (including LMWH), FXa-inhibiting oligosaccharides (e.g., fondaparinux), direct thrombin II inhibitors (e.g., desirudin), thrombolytic agents, glycoprotein IIb/IIIa receptor antagonists, thienopyridines (e.g., clopidogrel), dipyridamole, dextran, sulfinpyrazone, VKA, and other oral anticoagulants. Pharmacokinetic or PD interactions were not evident when apixaban was co-administered with aspirin 325 mg QD [65]. Co-administration of 500 mg naproxen with apixaban had no additional impact on platelet aggregation beyond that of naproxen [59]. Similarly, co-administration of apixaban with either clopidogrel (75 mg QD), prasugrel (60 mg followed by 10 mg QD), or the combination of clopidogrel 75 mg and aspirin 162 mg QD did not show a relevant increase in template bleeding time or further inhibition of platelet aggregation compared with administration of the antiplatelet agents without apixaban [65, 66]. Increases in clotting tests (PT, INR, and aPTT) were consistent with the effects of apixaban alone (data on file). Despite these findings, apixaban should be used with caution when co-administered with nonsteroidal anti-inflammatory drugs (including aspirin) and other antiplatelet agents because these medicinal products typically increase the bleeding risk and some individuals may have a more pronounced PD response when antiplatelet agents are co-administered with apixaban.

In a thorough QT study, apixaban had no effect on the QTc interval, with a peak placebo-adjusted, time-matched, Fridericia-corrected change from baseline QTc (ΔΔQTc) interval of 1.51 ms (one-sided upper 95% CI 3.71 ms) following administration of a supratherapeutic dose of 50 mg QD for 3 days [38].

A population-PK analysis was performed using data from the phase I studies and ~ 1000 subjects receiving apixaban after a total knee or hip replacement in phase II/III clinical trials [40]. The results showed that apixaban clearance decreased with increasing age and was lower in female subjects compared with male subjects (< 25% impact on apixaban AUC exposure). Subjects with mild, moderate, and severe renal impairment were predicted to have median AUC exposures at steady state ~ 15%, 38%, and 58% higher, respectively, than for subjects with normal renal function. Apixaban clearance was slightly lower immediately after surgery (< 25%), returning close to the pretreatment value by the fourth day after surgery. The reduced blood flow to the liver, kidney, and gastrointestinal tract might result in this change in apixaban clearance in the days after surgery.

A population-PK analysis was performed using data from the phase I studies and ~ 700 subjects receiving apixaban for VTE treatment or prevention of recurrent VTE in phase II/III clinical trials [41]. The results showed that age, sex, and Asian race had a < 25% impact on apixaban AUC exposure while subjects with severe renal impairment were predicted to have a 56% higher exposure than subjects with normal renal function. There was no difference in apixaban pharmacokinetics between healthy subjects and subjects receiving apixaban for VTE treatment or prevention of recurrent VTE: for a typical subject (60-year-old non-Asian male individual weighing 85 kg with CrCl of 100 mL/min), the apparent renal and non-renal clearance of apixaban were estimated to be 1.83 L/h and 2.52 L/h, respectively.

A population-PK analysis was performed to describe apixaban pharmcokinetics in subjects with NVAF including data from the phase I studies and ~ 3000 NVAF subjects in phase II/III clinical trials [42]. Predictive covariates of apixaban pharmacokinetics included age, sex, Asian race, renal function, and patient status (NVAF subjects vs. healthy subjects), although individual covariate effects generally resulted in a < 25% change in apixaban exposure, except for severe renal impairment, which resulted in an apixaban exposure increase of 55%. The effect of Japanese race was assessed as an ad-hoc analysis and found to be small, consistent with the effect of Asian race. Subjects with NVAF were estimated to have a slightly higher apixaban AUC exposure compared with phase I subjects (< 20%). In subjects whose apixaban dose was reduced to 2.5 mg BID because they met at least two of the three criteria (age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL), apixaban median AUC was ~ 27% lower than that in subjects receiving 5 mg BID, and there was a large overlap between the two dose groups.

In VTE prevention in orthopedic surgery subjects, a Cox proportional hazards model showed a statistically significant relationship between individual daily AUC at steady state and any bleeding endpoint [40]; a two-fold increase in apixaban daily AUC is expected to increase bleeding frequencies from 6.18% to 7.25% and from 9.32% to 10.9% in subjects following knee or hip replacement surgery, respectively. There was no statistically significant relationship between apixaban exposure and VTE outcomes using logistic regression [67]. The predicted daily AUC at steady state, C_max, or minimum plasma concentration and their corresponding anti-FXa activity values showed that there was considerable overlap in the individual predicted values for those with or without bleeding (data on file). Similar observations were made for apixaban exposure and bleeding endpoints in subjects with NVAF (data on file).

For the treatment of VTE or prevention of recurrent VTE, logistic regression analyses were performed between individual daily AUC at steady state and bleeding endpoint (composite of adjudicated major or adjudicated clinically relevant nonmajor bleeding) or efficacy endpoint (adjudicated symptomatic VTE or VTE-related death) [41]. The results found no statistically significant relationship for either bleeding or efficacy endpoints and showed that the range of individual predicted values of daily AUC at steady state, C_max, minimum plasma concentration, and the corresponding anti-FXa activity values for subjects with efficacy or bleeding events was entirely contained within the range of values from subjects without events [41]. Considering these data, there is no defined therapeutic exposure range or discernable threshold of apixaban concentration that would predict safety or efficacy outcomes for individual subjects.

After incorporating important covariates, apixaban pharmacokinetics exhibited moderate between-subject variability: ~ 40% and ~ 25% for oral plasma clearance and central volume of distribution, respectively, in the final population-PK analyses. The residual unexplained variability was ~ 30%.

While treatment with apixaban does not require routine monitoring of exposure, knowledge of apixaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery. The final population-PK and PK–anti-FXa activity models developed for each indication were used for simulations to predict the steady-state apixaban and anti-FXa activity levels in target patients. These exposure levels predicted from the population-PK and PK–anti-FXa activity analyses for each indication and at each dose level are summarized in Table 3 [3, 42]. While anti-FXa activity was reported in LMWH units in multiple apixaban clinical studies, the current assay uses an apixaban-specific calibrator and anti-FXa activity values are reported in apixaban concentration units, enabling a timely evaluation of apixaban exposure [31, 68]. Apixaban clinical studies that used both LMWH and apixaban calibrators and controls demonstrate a very high correlation between methods [35, 39]. Considering that apixaban exposure and anti-FXa activity are expected to fluctuate within a dosing interval, in contrast to INR with warfarin, it is critical to examine adherence and to accurately collect previous dosing history and time of blood sample when interpreting exposure levels, especially in routine care settings [69]. It should also be noted that factors such as impaired hepatic function and administration of exogenous PCC known to impact other clotting tests (INR, PT) do not impact apixaban anti-FXa activity determined with a one-step chromogenic assay regardless of the calibrators and controls used (i.e., results reported in LMWH units or ng/mL).